Comparison
3p Syndrome C4706503 vs 2 Hydroxyglutarate Aciduria C5139239
Clinical comparison between 3P Syndrome and 2 Hydroxyglutarate Aciduria for differential diagnosis and treatment planning.
3p Syndrome C4706503
A rare chromosomal disorder involving deletion of genetic material from chromosome 3. It causes distinctive facial features, growth delays, and intellectual disability. Care involves managing developmental and medical complications.
2 Hydroxyglutarate Aciduria C5139239
A metabolic disorder causing buildup of 2-hydroxyglutaric acid. It may affect the brain and nervous system. Management includes supportive therapies and monitoring for complications.
6 comparison axes
Onset
3p Syndrome C4706503
0-0
2 Hydroxyglutarate Aciduria C5139239
0-10
Onset patterns differ
Severity
3p Syndrome C4706503
severe
2 Hydroxyglutarate Aciduria C5139239
moderate
Different severity levels
Chronic
3p Syndrome C4706503
Chronic
2 Hydroxyglutarate Aciduria C5139239
Chronic
Differing course
Communicable
3p Syndrome C4706503
No
2 Hydroxyglutarate Aciduria C5139239
No
Different transmission
Body System
3p Syndrome C4706503
congenital
2 Hydroxyglutarate Aciduria C5139239
metabolic
Same/different system
Category
3p Syndrome C4706503
genetic
2 Hydroxyglutarate Aciduria C5139239
metabolic
Different category
Bottom line
3p-syndrome-C4706503 and 2-hydroxyglutarate-aciduria-C5139239 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3p Syndrome C4706503 | 2 Hydroxyglutarate Aciduria C5139239 | Discriminating power |
|---|---|---|---|
| Developmental delay | Often present from early life with intellectual disability and growth delay. | Neurologic effects may emerge during childhood; timing is variable. | Moderate |
| Facial features | Distinctive facial features are described as part of the syndrome. | No characteristic facial pattern is established by the supplied data. | Moderate |
| Neurologic course | Primarily a congenital developmental disorder rather than a metabolic accumulation. | May affect the brain and nervous system through metabolic accumulation. | High |
When to favor each condition
Choose 3p Syndrome C4706503 when
Congenital features at birth
Onset is listed as birth, supporting a chromosomal developmental diagnosis.
High
Growth delay with intellectual disability
These features are explicitly described for 3p syndrome.
Moderate
Suspected chromosomal deletion
The condition is defined by deletion of material from chromosome 3.
High
Choose 2 Hydroxyglutarate Aciduria C5139239 when
Childhood neurologic concern
Onset may occur from birth through age 10, unlike the birth-only pattern listed for 3p syndrome.
Moderate
Suspected organic acid accumulation
The disorder is defined by buildup of 2-hydroxyglutaric acid.
High
Metabolic rather than structural genetic presentation
The supplied category is metabolic, although genetic causes may underlie it.
Moderate
How key tests differ
| Test | 3p Syndrome C4706503 | 2 Hydroxyglutarate Aciduria C5139239 | Interpretation |
|---|---|---|---|
| Chromosomal analysis | May identify deletion involving chromosome 3. | Not expected to establish this metabolic diagnosis. | A chromosomal finding supports 3p syndrome but does not exclude unrelated conditions. |
| Urine organic acid testing | No characteristic organic-acid pattern is established here. | May show elevated 2-hydroxyglutaric acid; exact cutoff is not supplied. | An abnormal metabolite result requires clinician and laboratory interpretation. |
| Neuroimaging | No specific imaging pattern is established by the source. | Brain involvement is possible, but findings are not specified. | Imaging may support clinical assessment but is not diagnostic alone. |
Prognosis comparison
3p Syndrome C4706503
- Outcome
- Chronic congenital condition with potentially substantial developmental impact.
- Factors
- Severity, associated medical complications, and developmental support.
2 Hydroxyglutarate Aciduria C5139239
- Outcome
- Chronic metabolic condition with variable neurologic impact; exact prognosis is not established.
- Factors
- Age at recognition, neurologic involvement, and response to supportive care.
Time frame: Lifelong monitoring is generally relevant; precise milestones are not established.
Individual prognosis requires clinician interpretation and cannot be inferred from labels alone.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental complications | Growth delay and intellectual disability are described. Neurologic complications may occur, but specific deficits are not established. Both require individualized developmental support. |
| Medical complexity | Care focuses on developmental and medical complications. Care includes supportive therapy and complication monitoring. Complication profiles should not be assumed beyond the source. |
| Disease course | Listed as severe and chronic. Listed as moderate and chronic. Severity labels do not predict an individual outcome. |
Patient education highlights
- HighDifferent causes
One is a chromosomal deletion disorder; the other involves metabolic accumulation.
- HighSpecialist follow-up
Genetics, developmental, and metabolic clinicians may coordinate evaluation and care.
- MediumSupportive management
Neither description establishes a specific curative treatment or dose.